English reimbursement for Immunocore’s Kimmtrak

5 December 2024

Immunocore Holdings (Nasdaq: IMCR) has announced that Kimmtrak (tebentafusp) has been recommended for funding through the National Health Service in England by the National Institute for Health and Care Excellence (NICE).

The NICE has recommended Kimmtrak within its marketing authorization for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma affecting the eye.

The recommendation overturns the initial negative decision by the NICE in May 2023, which was successfully appealed against in December 2023 by Immunocore, an Oxfordshire-based biotech focused on immunomodulating medicines for patients with cancer, infectious diseases and autoimmune diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK